The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis

Elena Cortés-Vicente1,2, Ricard Rojas-García1,2, Jordi Díaz-Manera1,2, Luis Querol1,2, Carlos Casasnovas3, Antonio Guerrero-Sola4, José Luis Muñoz-Blanco5, José Eulalio Bárcena-Llona6, Celestino Márquez-Infante7, Julio Pardo8, Eva María Martínez-Fernández9, Mercedes Usón10, Pedro Oliva-Nacarino11, Teresa Sevilla12,13 & Isabel Illa1,12.

1Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
2Centre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain
3Neuromuscular Diseases Unit, Department of Neurology, Hospital Universitari de Bellvitge – IIBELL, L’Hospitalet de Llobregat, Barcelona, Spain
4Neuromuscular Diseases Unit, Department of Neurology, Hospital Universitario Clínico San Carlos, Madrid, Spain
5ALS-Neuromuscular Unit, Department of Neurology, Hospital General Universitario Gregorio Marañón, IISGM, Madrid, Spain
6Department of Neurology, Hospital Universitario Cruces, Baracaldo, Spain
7Neuromuscular Diseases Unit, Department of Neurology and Neurophysiology, Hospital Universitario Virgen del Rocío, Sevilla, Spain
8Department of Neurology, Hospital Clínico, Santiago de Compostela, Spain
9Department of Neurology, Hospital Juan Ramón Jiménez, Huelva, Spain
10Department of Neurology, Hospital Son Llátzer, Palma de Mallorca, Spain
11Department of Neurology, Hospital Universitario Central de Asturias, Oviedo, Spain
12Neuromuscular Unit, Department of Neurology, Hospital Universitari i Politècnic La Fe, Valencia, Spain
13Department of Medicine, University of Valencia, Valencia, Spain

Correspondence
Isabel Illa, Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Sant Antoni Maria Claret 167, Barcelona 08025, Spain. Tel: 0034 935565986; Fax: 0034 935565602; E-mail: illa@santpau.cat

Funding Information
I. Illa received research support from the Fondo de Investigación en Salud, Instituto de Salud Carlos III, Ministry of Health (Spain), FIS PI16/01440 (Fondos FEDER). E. Cortés-Vicente was supported by a FIS grant (CM16/00096) from Fondo de Investigación en Salud, Instituto de Salud Carlos III, Ministry of Health (Spain) and Fondo Social Europeo.

Received: 2 February 2018; Revised: 7 March 2018; Accepted: 20 March 2018

Abstract

Objective: To evaluate whether the clinical benefit and relapse rates in anti-muscle-specific kinase (MuSK) myasthenia gravis (MG) differ depending on the protocol of rituximab followed. Methods: This retrospective multicentre study in patients with MuSK MG compared three rituximab protocols in terms of clinical status, relapse, changes in treatment, and adverse side effects. The primary effectiveness endpoint was clinical relapse requiring a further infusion of rituximab. Survival curves were estimated using Kaplan–Meier methods and survival analyses were undertaken using Cox proportional-hazards models.

Results: Twenty-five patients were included: 11 treated with protocol 4 + 2 (375 mg/m²/4 weeks, then monthly for 2 months), five treated with protocol 1 + 2 (two 1 g doses 2 weeks apart), and nine treated with protocol 1 (two 1 g doses 2 weeks apart). Relapse occurred in 18.2%, 80%, and 33.3%, and mean time to relapse was 3.5 (SD 1.5), 1.1 (SD 0.4), and 2.5 (SD 1.4) years, respectively. Based on Kaplan–Meier estimates, patients treated with protocol 4 + 2 had fewer and later relapses than patients treated with the other two protocols (log-rank test P = 0.0001). Patients treated with protocol 1 + 1 had a higher risk of relapse than patients treated with protocol 4 + 2 (HR 112.8, 95% CI 5.7–2250.4, P = 0.002). Patients treated with protocol 4 showed a trend to a higher risk of relapse than those treated with protocol 4 + 2 (HR 9.2, 95% CI 0.9–91.8, P = 0.059).

Interpretation: This study provides class IV evidence that the 4 + 2 rituximab protocol has a lower clinical relapse rate and produces a more durable response than the 1 + 1 and 4 protocols in patients with MuSK MG.
Introduction

Myasthenia gravis (MG) is an autoimmune disease caused by antibodies to antigens of the postsynaptic neuromuscular junction and clinically characterized by fatigable muscle weakness.1–5 Approximately, 5% of MG patients have autoantibodies against muscle-specific kinase (MuSK),6,7 and the frequency is higher if an IgG-specific MuSK-cell-based assay is used to detect these antibodies.8 MuSK antibody titers are mainly of the IgG4 subclass and considered to correlate with patients’ clinical status.9,10 Patients with MuSK MG often present early, severe bulbar and respiratory involvement. Furthermore, they have a poorer response to acetylcholine esterase inhibitors, standard immunosuppressant therapies, and intravenous immunoglobuline than MG patients without MuSK.10 For these reasons, the need for an efficient drug to treat patients with MuSK MG has long been awaited.

Rituximab, a monoclonal antibody that targets the CD20 antigen in B cells, was first used to treat non-Hodgkin’s B-cell lymphoma.11–13 However, it later emerged as a highly effective tool to manage autoimmune diseases.14,15 As autoreactive B cells have a clear pathogenic role in the development of MG, rituximab has been used in drug-resistant MG patients and several authors have described its benefits.16–20 Rituximab has proven to be more effective and to have a longer clinical benefit in patients with antibodies against MuSK21,22 than in patients with anti-acetylcholine receptor (AChR)-positive MG.

Rituximab has also shown to be a remarkably effective drug in other IgG4-mediated diseases of the central and peripheral nervous system and connective tissue of the skin or kidneys, such as CIDP with anti-Contactin-1 and anti-Neurofascin-155 antibodies,21 pemphigus,22 membranous glomerulonephritis,23 and LG11 limbic encephalitis.24 All IgG4-mediated disorders seem to share similarities in epitope binding, human leukocyte antigen associations, disease mechanism, and underlying etiology, thus explaining the extraordinary response to rituximab observed in all such disorders.25

We previously reported the benefits of rituximab in a large series of drug-resistant patients (11 AChR-positive MG and 6 MuSK-positive MG). Remarkably, all six patients with MuSK MG achieved minimal manifestations (MM) or a better Myasthenia Gravis Foundation of America post-intervention status (MGFA PIS), and no additional infusions were required during a 31-month follow-up (4–60). The protocol we used was 375 mg/m2 weekly for 4 weeks, then monthly for 2 months (4 + 2).17 Infusion protocols for rituximab in autoimmune disorders4,17–25 differ, and no protocol has yet been established for rituximab in MuSK MG. We wondered whether our treatment regimen contributed to the excellent long-term outcome of MuSK MG. Here, we describe the clinical follow-up in 25 patients with MuSK MG treated with different infusion protocols of rituximab. We report the clinical effectiveness, adverse effects, and differences in clinical outcomes in patients treated with the three most commonly used rituximab treatment protocols.

Methods

Patients and clinical evaluation

In this multicentre, retrospective observational study, we included all patients with MuSK MG treated with rituximab at 11 hospitals in Spain between January 1, 2006 and March 31, 2016. We collected demographic and clinical data at onset and during follow-up. Patients were followed until November 30, 2017. To assess the clinical response, the MGFA PIS was determined periodically, and relapse rate and changes in treatment were recorded. The primary effectiveness endpoint was clinical relapse requiring a further infusion of rituximab. Safety was evaluated based on the effects of rituximab treatment on mortality and morbidity.

Treatment protocol

The standard treatment protocol for patients with MuSK MG is first-line prednisone and second-line immunosuppressors (azathioprine/mycophenolate followed by cyclosporine) if the response is not adequate or if the dose of prednisone required is higher than 40 mg every other day. Patients were considered drug-resistant when no significant clinical improvement was achieved after prednisone and at least two second-line immunosuppressants.31 Patients with MGFA IV or V and no response to prednisone were treated with rituximab as a second-line drug in accordance with our previous results.17 Rituximab was administered following one of three protocols: (4 + 2) 375 mg/m2 every week for four consecutive weeks and then monthly for the next 2 months; (1 + 1) two 1 g doses separated by 2 weeks; and (4) 375 mg/m2 every week for four consecutive weeks. Rituximab re-infusions were administered only if patients relapsed. A relapse was defined as the reappearance of myasthenic symptoms that limited daily activity.

Protocol approval and patients’ informed consent

Informed consent was obtained from all patients and the study was approved by the ethics committees at all
participating hospitals. Permission for compassionate use of rituximab was given by the Spanish Ministry of Health.

**Statistical analysis**

A descriptive data analysis was performed. Demographic characteristics are reported as means and standard deviations (SD) for quantitative variables and as percentages for categorical variables. Differences between patient subgroups in baseline characteristics were evaluated using ANOVA to compare categorical variables and the Mann–Whitney U test to compare quantitative variables. Log-rank tests were used to compare Kaplan–Meier estimates for survival curves for the three treatment groups in a time-to-first-event analysis. Hazard ratios and 95% confidence intervals were estimated using a Cox proportional-hazards model. Survival time was from the date of the first rituximab dose to date of reinfusion due to clinical relapse. Patients with no relapse were censored at date of last follow-up. Data analysis was carried out using Stata 13.0 (StataCorp, College Station, TX) for Windows.

**Results**

Twenty-five patients with MuSK MG were included in the study: 11 were treated with protocol 4+2, five were treated with protocol 1+1, and nine were treated with protocol 4. Table 1 summarizes the demographic and clinical characteristics of the three treatment groups. The only significant difference between groups in baseline characteristics in the univariate analyses was age at onset (P = 0.035). Age at which rituximab was started did not differ significantly between groups (P = 0.449). Treatment with rituximab was associated with a significant improvement in all patients, and all achieved MM or a better MGFA PIS. After rituximab was started, other treatment, especially prednisone, was decreased or withdrawn in all patients (Table 2). Patients were followed up for a mean of 5.0 years (SD 3.3).

No patient presented severe adverse events. During the infusion, seven patients presented mild symptoms: three of the 11 patients in the 4+2 protocol group (one facial paresthesias, one fever, and one skin and mucous itching); one of the five patients in the 1+1 protocol group (mild gastrointestinal symptoms); and three of the nine patients in the protocol 4 group (two patients with skin rash and one fatigue). All these symptoms disappeared when premedication with antihistamine and steroid treatment was given before further infusions of rituximab.

Relapse occurred in two patients in group 4+2, in four patients in group 1+1, and in three patients in group 4, resulting in relapse rates of 18.2%, 80%, and 33.3%, respectively. The mean time to relapse was 3.5 years (SD 1.5, Min 2.5–Max 4.6), 1.1 years (SD 0.4, Min 0.7–Max 1.6), and 2.5 years (SD 1.4, Min 1.2–Max 4.1), respectively. Kaplan–Meier estimates showed a clear difference in survival curves among groups, with patients treated with protocol 4+2 having fewer relapses (log-rank test P = 0.0001). Survival curves are shown in Figure 1.

### Table 1. Demographic and clinical data of patients included in the study and comparison between groups.

|                        | 4+2 doses (n = 11) | 1+1 (n = 5) | 4 doses (n = 9) | P   |
|------------------------|-------------------|-------------|----------------|-----|
| **Age at onset (years)** |                   |             |                |     |
| Mean (SD)              | 47.2 (15.7)       | 39.5 (17.4) | 30.5 (9.6)     | 0.035 |
| Min–Max                | 14.7–73.8         | 18.3–65.9   | 17.0–45.9      |     |
| **Sex (% female)**     |                   |             |                |     |
| 11 (100%)              | 4 (80%)           | 9 (100%)    |                | 0.200 |
| **Worst MGFA class**   |                   |             |                |     |
| IIIB 3 (27.3%)         | IIIB 2 (40%)      | IIIB 6 (66.7%) |             | 0.073 |
| IVB 6 (54.5%)          | IVB 1 (20%)       | IVB 1 (11.1%) |             |     |
| V 2 (18.2%)            | V 1 (20%)         |             |               |     |
| **Age when RTX was started (years)** |             |             |                |     |
| Mean (SD)              | 55.4 (12.5)       | 46.3 (21.9) | 49.2 (16.5)    | 0.449 |
| Min–Max                | 35.3–78.9         | 19.4–78.9   | 26.5–70.1      |     |
| **Best MGFA PIS**      |                   |             |                |     |
| CRS 5 (45.4%)          | CSR 1 (20%)       | CSR 1 (11.1%) |             | 0.335 |
| PR 2 (18.2%)           | PR 3 (60%)        | PR 2 (22.2%) |             |     |
| MM 4 (36.4%)           | MM 1 (20%)        | MM 6 (66.7%) |             |     |
| **Follow-up (years)**  |                   |             |                |     |
| Mean (SD)              | 6.6 (3.5)         | 3.5 (1.9)   | 4.0 (3.3)      | 0.114 |
| Min–Max                | 1.4–11.6          | 1.3–6.3     | 1.6–11.7       |     |
| **MGFA PIS last visit**|                   |             |                |     |
| CRS 4 (36.4%)          | CRS 2 (40%)       | CRS 1 (11.1%) |         | 0.665 |
| PR 1 (9.1%)            | PR 2 (20%)        | PR 2 (22.2%) |             |     |
| MM 6 (54.6%)           | MM 2 (40%)        | MM 6 (66.7%) |             |     |
Table 2. Previous treatments, treatment before rituximab, and treatment at last evaluation for each patient. Time regarding how long treatment was provided both for treatment before rituximab and treatment at last visit are provided in brackets.

| Patient | Rituximab protocol | Previous treatments | Treatment before rituximab (treatment duration) | Treatment at last visit (treatment duration) |
|---------|--------------------|---------------------|-------------------------------------------------|---------------------------------------------|
| 1       | 4 + 2              | Pyridostigmine, PDN, IVIG | Pyridostigmine 300 mg per day (6 months), PDN 60 mg per day (1 month) | None (53 months)                                |
| 2       | 4 + 2              | Pyridostigmine, DFZ, CYA | DFZ 30 mg EOD (99 months), CYA 150 mg every 12 h (87 months), Pyridostigmine 300 mg per day (99 months) | DFZ 6 mg EOD (61 months), Pyridostigmine 240 mg per day (61 months) |
| 3       | 4 + 2              | PDN, IVIG, CYA        | PDN 60 mg EOD (4 months), CYA 100 mg every 12 h (2 months) | None (59 months)                                |
| 4       | 4 + 2              | PDN, AZA, MMF, CYA, IVIG | PDN 65 mg EOD (48 months), CYA 150 mg per day (9 months) | PDN 10 mg EOD (23 months)                      |
| 5       | 4 + 2              | PDN, IVIG, CYA        | PDN 60 mg per day (2 months) | PDN 40 mg EOD (17 months)                      |
| 6       | 4 + 2              | PDN, THYM, AZA, IVIG, CYA | Pyridostigmine if needed (38 months) (CPH abandoned 19 months before) | None (24 months)                                |
| 7       | 4 + 2              | THYM, PDN, AZA, IVIG, CYA | MMF 2 g per day (3 months) | None (96 months)                                |
| 8       | 4 + 2              | PDN, THYM, AZA, MMF, CYA, IVIG, CYH | PDN 15 mg EOD (5 months, 245 months in total with PDN), MMF 2 g per day (3 months) | PDN 30 mg EOD (18 months)                      |
| 9       | 4 + 2              | PDN, AZA              | PDN 40 mg EOD (19 months, 79 months in total with PDN) | None (29 months)                                |
| 10      | 4 + 2              | PDN, AZA, IVIG, CYA, CPLEX | PDN 30 mg EOD (18 months, 51 months in total with PDN), CYA 125 mg per day (6 months) | Pyridostigmine if needed (30 months)           |
| 11      | 4 + 2              | PDN, AZA, CYA, IVIG, Pyridostigmine | PDN 80 mg EOD (28 months), Pyridostigmine 300 mg per day (29 months) | PDN 7 mg EOD (3 months)                        |
| 12      | 1 + 1              | Pyridostigmine, PDN, MMF | PRD 60 mg EOD (1 month), Pyridostigmine if needed | PDN 10 mg EOD (7 months)                      |
| 13      | 1 + 1              | PDN                  | PDN 25 mg EOD (6 months), Pyridostigmine if needed | None (12 months) (rituximab when relapse)      |
| 14      | 1 + 1              | PDN                  | PDN 60 mg/30 mg EOD (4 months) | None (35 months)                                |
| 15      | 1 + 1              | PDN, AZA, MMF        | PDN 40 mg per day (1 month, 223 months in total with PDN) | PDN 12.5 mg per day (29 months)                |
| 16      | 1 + 1              | IVIG, PDN, MMF, PLEX, CYA | PDN 45 mg EOD (47 months), CYA 100 mg every 12 h (10 months), Pyridostigmine 240 mg every day (11 months) | Pyridostigmine if needed (21 months)           |
| 17      | 4                  | THYM, Pyridostigmine, PDN, TAC, PLEX | PDN 5 mg EOD (60 months), TAC 2 mg every 12 h (10 months), Pyridostigmine 120 mg per day (96 months) | None (20 months)                                |
| 18      | 4                  | PDN, THYM, IVIG, AZA  | PDN 20 mg per day (36 months), MMF 1 g per day (24 months) | MMF 1.500 g per day (30 months)               |
| 19      | 4                  | Pyridostigmine, PDN, TAC, IVIG, PLEX | TAC 1, 5 mg every 12 h (23 months), PDN 20 mg EOD (23 months), Pyridostigmine 180 mg per day (35 months) | CYA 125 mg every 12 h (23 months), PDN 50 mg EOD (23 months) |
| 20      | 4                  | Pyridostigmine, PDN, AZA, PLEX, IVIG, THYM | PDN 30 mg EOD (264 months), Pyridostigmine 360 mg per day (265 months) | PDN 10 mg per day (45 months)                  |
| 21      | 4                  | Pyridostigmine, PDN, AZA, PLEX, IVIG, THYM | PDN 30 mg per day (300 months) | PDN 10 mg per day (53 months)                  |
| 22      | 4                  | Pyridostigmine, PDN, AZA, PLEX, IVIG, THYM | AZA 111 mg per day (60 months) | None (21 months)                                |
| 23      | 4                  | Pyridostigmine, PDN, AZA, IVIG, PLEX | AZA 111 mg per day (60 months), PDN 30 mg EOD (120 months) | PDN 10 mg EOD (26 months)                      |
| 24      | 4                  | Pyridostigmine, PDN, AZA, MMF | MMF 2.5 g per day (45 months), PDN 30 mg/15 mg EOD (71 months) | PDN 10 mg EOD (12 months)                      |
| 25      | 4                  | PDN, MTX, AZA, MMF, IVIG, PLEX | PDN 70 mg per day (106 months) | None (116 months)                                |

PDN, prednisone; DFZ, Deflazacort; AZA, azathioprine; MMF, Mycophenolate mofetil; CYA, cyclosporine; TAC, Tacrolimus; CPH, cyclophosphamide; MTX, methotrexate; IVIG, intravenous immunoglobulin; PLEX, plasma exchange; THYM, thymectomy; EOD, Every other day.
The Cox proportional-hazards regression model showed that patients treated with protocol 1 + 1 had a higher risk of relapse and a greater need for reinfusion with rituximab than patients treated with protocol 4 + 2 (hazard ratio [HR] 112.8, 95% confidence interval [CI], 5.7–2250.4, \( P = 0.002 \)). Patients treated with protocol 4 also showed a trend to a higher risk of relapse than patients treated with protocol 4 + 2 (HR 9.2, 95% CI 0.9–91.8, \( P = 0.059 \)) (likelihood ratio test = 15.1, \( P = 0.0005 \)).

**Discussion**

Rituximab has previously shown level IV evidence as a beneficial and durable treatment option for drug-resistant MuSK MG.\(^7\)\(^2\)\(^0\) Our results further add that the treatment protocol plays a key role in reducing clinical relapse and achieving a long-lasting response. All patients included in this study improved after rituximab treatment and all patients achieved MM or a better MGFA PIS and a long-lasting response after an extended follow-up. Moreover, prednisone and other immunosuppressive therapies were withdrawn or tapered to lower doses in all cases. Rituximab was also found to be safe as no patient developed severe side effects. The frequency of mild-moderate adverse events did not differ between the three groups. This finding is of particular note because most patients had been treated previously with two or more immunosuppressive therapies. Close follow-up is recommended, however, as several cases of side effects of rituximab have been reported in patients with MG.\(^3\)\(^2\)

Various protocols of rituximab have been published to treat patients with MuSK MG, and relapse rates and durability of response have differed.\(^1\)\(^7\)\(^,\)\(^2\)\(^0\) As no infusion regimen has yet been standardized in this setting, we compared the clinical response of 25 MuSK MG patients treated with three different rituximab protocols. Because all patients responded to the drug, the primary effectiveness endpoint chosen was the appearance of a clinical relapse requiring a further infusion of rituximab. Based
on Kaplan–Meier estimates, the most efficient protocol was the $4 + 2$ protocol. It showed the lowest relapse rate (18.2%) and the longest time to relapse after an extended follow-up period. The Cox proportional-hazards regression confirmed that patients treated with protocol $1 + 1$ had a significantly higher risk of relapse and greater need for reinfusion with rituximab than patients receiving the $4 + 2$ protocol. Patients treated with the protocol based on four doses also showed a trend toward a significantly higher risk of relapse than those treated with protocol $4 + 2$.

Although prominent B-cell pathology has been described in MuSK MG, the mechanism by which IgG4 antibodies are produced remains unclear. Rituximab works by depleting pre-B cells and mature and memory B cells from the circulation. Exactly how this leads to antibody reduction, however, is still to be determined as B-cell populations that do not express CD20 produce a considerable portion of circulating immunoglobulin. Why some patients relapse and other do not is unclear. A recent study of autoantibody-producing cells during disease relapse in three MuSK MG subjects who had previously achieved rituximab-induced remission revealed autoantibody-expressing CD27+ B plasmablasts within the reconstituted repertoire during relapse but not during remission or in controls. The authors proposed that MuSK-specific memory cells continuously supply a population of short-lived, autoantibody-secreting plasmablasts, and suggested that rituximab works by indirectly depleting the CD20− plasmablast population by diminishing CD20+ memory B cells. Alternatively, they hypothesized that rituximab could work by directly depleting a fraction of plasmablasts that may be CD20+.

In our study, we observed that all patients with MuSK MG treated with rituximab had a beneficial response. However, the relapse rate differed depending on the posology used, with the $4 + 2$ protocol being the most effective in terms of response durability. We hypothesize that this protocol is more efficacious in depleting the pool of plasmablasts-progenitor CD20− memory B cells or the subset of CD20+ plasmablasts than the two other protocols followed. Further studies are needed to confirm this hypothesis.

The main limitation of our study is the small number of patients. MuSK MG is a rare disorder, however, and as not all cases are severe or drug-resistant, rituximab is not always required. The strengths of the study are the significant results in the statistical analysis, and particularly the long clinical follow-up, with an overall mean of 5 years.

In summary, our findings add to the evidence that rituximab is effective and safe in the treatment of MuSK MG. We recommend treating patients with a sole induction regimen of rituximab following the protocol $4 + 2$ (375 mg/m² every week for 4 consecutive weeks and then monthly for the next 2 months), since this protocol ensures a minimal rate of clinical relapse and a long-lasting response to rituximab. To minimize potential adverse events, we recommend re-treating patients with rituximab in cases of clinical relapse only.

Acknowledgments

The authors would like to acknowledge the Department of Medicine at the Universitat Autònoma de Barcelona.

Conflicts of Interest

None.

References

1. Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 2015;14:1023–1036.
2. Berrih-Aknin S, Sourroujon MC. Cutting edge in myasthenia gravis. Autoimmun Rev 2013;12:861–862.
3. Drachman DB, de Silva S, Ramsay D, Pestronk A. Humoral pathogenesis of myasthenia gravis. Ann N Y Acad Sci 1987;505:90–105.
4. Engel AG, Lindstrom JM, Lambert EH, Lennon VA. Ultrastructural localization of the acetylcholine receptor in myasthenia gravis and in its experimental autoimmune model. Neurology 1977;27:307–315.
5. Querol L, Ila I. Myasthenia gravis and the neuromuscular junction. Curr Opin Neurol 2013;26:459–465.
6. Hoch W, McConville J, Helms S, et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7:365–368.
7. McConville J, Farrugia ME, Beeson D, et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 2004;55:580–584.
8. Huda S, Waters P, Woodhall M, et al. IgG-specific cell-based assay detects potentially pathogenic MuSK-Abs in seronegative MG. Neurol Neuroimmunol Neuroinflamm 2017;4:e357.
9. Huijbers MG, Zhang W, Klooster R, et al. MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4. Proc Natl Acad Sci USA 2013;110:20783–20788.
10. Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003;126(pt 10):2304–2311.
11. Anderson DR, Grillo-López A, Varrus G, et al. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin’s B-cell lymphoma. Biochem Soc Trans 1997;25:705–708.
12. Maloney DG, Grillo-López AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 1997;90:2188–2195.

13. Tobinai K, Kobayashi Y, Narabayashi M, et al. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. Ann Oncol 1998;9:527–534.

14. Edwards JC, Leandro MJ, Cambridge G. B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders. Biochem Soc Trans 2002;30:824–828.

15. Looney RJ. Treating human autoimmune disease by depleting B cells. Ann Rheum Dis 2002;61:863–866.

16. Lebrun C, Bourg V, Tieulie N, Thomas P. Successful treatment of refractory generalized myasthenia gravis with rituximab. Eur J Neurol 2009;16:246–250.

17. Díaz-Manera J, Martínez-Hernández E, Querol L, et al. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 2012;78:189–193.

18. Robeson KR, Kumar A, Keung B, et al. Durability of the rituximab response in acetylcholine receptor autoantibody-positive myasthenia gravis. JAMA Neurol 2017;74:60–66.

19. Tandan R, Hehir MK, Waheed W, Howard DB. Rituximab treatment of myasthenia gravis: a systematic review. Muscle Nerve 2017;56:185–196.

20. Hehir MK, Hobson-Webb LD, Benatar M, et al. Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review. Neurology 2017;5:1069–1077.

21. Querol L, Nogales-Gadea G, Rojas-García R, et al. Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy. Ann Neurol 2013;73:370–380.

22. Querol L, Nogales-Gadea G, Rojas-García R, et al. Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVlg. Neurology 2014;82:879–886.

23. Querol L, Rojas-García R, Díaz-Manera J, et al. Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflamm 2015;2:e149.

24. Dupuy A, Viguier M, Bédane C, et al. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol 2004;140:91–96.

25. Roccatello D, Baldovino S, Rossi D, et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2004;19:3054–3061.

26. Lai M, Huijbers MG, Lancaster E, et al. Investigation of LG11 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 2010;9:776–785.

27. Irani SR, Pettingill P, Kleopa KA, et al. Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol 2012;72:241–255.

28. Ohkawa T, Fukata Y, Yamasaki M, et al. Autoantibodies to epilepsy-related LG11 in limbic encephalitis neutralize LG11-ADAM22 interaction and reduce synaptic AMPA receptors. J Neurosci 2013;33:18161–18174.

29. Huijbers MG, Querol LA, Niks EH, et al. The expanding field of IgG4-mediated neurological autoimmune disorders. Eur J Neurol 2015;22:1151–1161.

30. Roccatello D, Sciascia S, Baldovino S, et al. Improved (4 Plus 2) rituximab protocol for severe cases of mixed cryoglobulinemia: a 6-year observational study. Am J Nephrol 2016;43:251–260.

31. Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology 2016;87:419–425.

32. Kanth KM, Solorzano GE, Goldman MD. PML in a patient with myasthenia gravis treated with multiple immunosuppressing agents. Neurol Clin Pract 2016;6:e17–e19.

33. Guptill JT, Yi JS, Sanders DB, et al. Characterization of B cells in muscle-specific kinase antibody myasthenia gravis. Neurol Neuroimmunol Neuroinflamm 2015;2:e77.

34. Lee JY, Stathopoulos P, Gupta S, et al. Compromised fidelity of B-cell tolerance checkpoints in AChR and MuSK myasthenia gravis. Ann Clin Transl Neurol 2016;3:443–454.

35. Vander Heiden JA, Stathopoulos P, Zhou JQ, et al. Dysregulation of B cell repertoire formation in myasthenia gravis patients revealed through deep sequencing. J Immunol 2017;198:1460–1473.

36. Manz RA, Hauser AE, Hiepe F, Radbruch A. Maintenance of serum antibody levels. Annu Rev Immunol 2005;23:367–386.

37. Stathopoulos P, Kumar A, Nowak RJ, O’Connor KC. Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis. JCI Insight 2017;2:e94263. pii: 94263. https://doi.org/10.1172/jci.insight.94263.